Functional analysis of SRY variants in individuals with 46,XY differences of sex development

In mammals, male sexual development is initiated by the expression of the Sex-determining-Region-Y ( SRY ) gene. SRY contains a highly conserved High Mobility Group (HMG) box essential for DNA binding and activity. Variants in SRY cause Differences of Sex Development (DSD), accounting for 10-15% of 46,XY gonadal dysgenesis cases. Here, we present the functional analysis of five SRY coding variants identified in patients with 46,XY DSD. Four variants (p.Asp58Glu, p.Arg75Lys, p.Met85Thr, and p.Arg86Ter) are located within the HMG box and one variant (p.Tyr198Cysfs*18) located in the C-terminal domain. We functionally characterise the impact of these variants in vitro , investigating SRY localisation and transactivational activity using SOX9 regulatory elements that are responsive to SRY. We find that three variants (p.Met85Thr, p.Arg86Ter, and p.Tyr198Cysfs*18) have reduced or abolished transactivational activity suggesting these are pathogenic, with the p.Arg86Ter variant undetectable in our assays and the p.Met85Thr variant exhibiting reduced nuclear localisation. The pathogenic mechanisms underlying reduced activity of the novel elongated p.Tyr198Cysfs*18 variant is however unclear, although this variant also affected localisation. In contrast, two additional variants (p.Asp58Glu and p.Arg75Lys) had no discernable effects on nuclear localization or transactivational activity despite in silico analysis predicting impaired DNA binding. Taken together, our data establish the likely pathogenicity of these SRY variants and improve diagnostic certainty for the patients in which they were identified. • Functional analysis reveals change to some SRY variants subcellular localisation and activity. • In silico analysis show two variant may affect SRY-DNA interaction and SRY structure. • Functional study confirms the likely pathogenicity of some of these variants. • It provides an important resource for geneticist , genetic counsellors, and clinicians.